论文部分内容阅读
目的探讨凝血与纤溶功能变化在糖尿病微血管病变中的临床意义。方法纤溶酶原激活物抑制物-1(PAI-1)活性采用发色底物法,纤维蛋白原(Fg)采用免疫浊度法测定。结果糖尿病无微血管病变组血浆PAI-1和Fg水平高于正常对照组(P<0.05),糖尿病微血管病变组血浆PAI-1和Fg水平明显高于无微血管病变组及正常对照组(P<0.01)。结论2型糖尿病患者存在血液的高凝及低纤溶状态,在发生2型糖尿病微血管病变后更为明显,检测2型糖尿病患者血浆中PAI-1和Fg水平,对糖尿病微血管病变的预防和治疗具有一定的临床意义。
Objective To investigate the clinical significance of coagulation and fibrinolysis in diabetic microangiopathy. Methods The activity of plasminogen activator inhibitor-1 (PAI-1) was determined by the chromogenic substrate method, and the fibrinogen (Fg) by immunoturbidimetry. Results The levels of plasma PAI-1 and Fg in patients with diabetic microangiopathy were significantly higher than those in normal controls (P <0.05). The levels of plasma PAI-1 and Fg in patients with diabetic microangiopathy were significantly higher than those without microvascular disease and normal controls (P <0.01) ). Conclusions Patients with type 2 diabetes have hypercoagulable and fibrinolytic status of blood, which is more obvious after the occurrence of type 2 diabetic microangiopathy. The levels of PAI-1 and Fg in plasma of patients with type 2 diabetes mellitus and the prevention and treatment of diabetic microangiopathy Has some clinical significance.